Access Briefing: Germany Q4/24

🚨Get our latest update on HTA in Germany (AMNOG): Free download of our newsletter – and register for upcoming updates 📅📥

All resolutions by G-BA for HTA procedures of pharmaceuticals published in the fourth quarter of 2024:

Our highlights in a nutshell:

• 21 resolutions published by G-BA🏛️
• Osimertinib: Hint for major additional benefit for one subpopulation (highest category) 🔝
• Pembrolizumab: 33rd and 34th assessment💊
• Nivolumab: 28th assessment💉
• Iptacopan: Reimbursement with data generation💼
• Cefepim/ Enmetazobactam: Acknowledged as antibiotic of last resort💊⚠️
   

The stats:

• Major additional benefit: 1 (5%) ⭐
• Considerable additonal benefit: 2 (10%) 👍
• Minor additional benefit: 2 (10%) 👌
• Non quantifiable benefit: 4 (19%) 🙆
• No additional benefit proven: 11 (52%) ❌
• Additional benefit considered proven: 1 (5%) ✅  
   

Register here for upcoming issues of our Access Briefing: https://forms.office.com/e/Jt8bPmVkdJ📝

Link for free download: https://www.ecker-ecker.de/media/Newsletter_GER_2024-Q4_QC.pdf
 

Market Access is local 🌍. We offer a One Stop Shop for Europe: Together with our partner companies we cover all key European markets. 250 local Market Access experts from our network of partner companies follow one common methodology.